Cytogenetic changes of mesenchymal stem cells in the neoplastic bone marrow niche in leukemia

doi:10.1007/s11515-016-1408-0

Front. Biol.

2016, Vol. 11

Issue (4) : 305-310 https://doi.org/10.1007/s11515-016-1408-0

REVIEW

Cytogenetic changes of mesenchymal stem cells in the neoplastic bone marrow niche in leukemia

Shirin Ferdowsi¹,Shirin Azizidoost²,Nasim Ghafari³,Najmaldin Saki^2,^3,^*(

)

¹. Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran
². Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
³. Golestan Hospital Clinical Research Development Unit, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

Download: PDF(123 KB) HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks

Abstract

BACKGROUND: Bone marrow mesenchymal stromal cells (BM-MSCs) are an essential cell type in the hematopoietic microenvironment. The question of whether MSCs from patients with different leukemias have cytogenetic abnormalities is controversial. In this study, we attempted to review the cytogenetic profiles of MSCs in patients with leukemia, and verify whether these profiles were related to different ex vivo culture conditions or to chronic or acute disease states. This information could be useful in clarifying the origin of MSCs and developing clinical applications for this cell type.

METHODS: A systematic literature search was performed using the PubMed search engine. Studies published over the past 15 years, i.e., between 1995 and January 2015, were considered for review. The following keywords were used: “cytogenetic,” “leukemia,” “bone marrow,” and “mesenchymal stromal cells.”

RESULTS: Some studies demonstrated that BM-MSCs are cytogenetically normal, whereas others provided evidence of aberrations in these cells.

CONCLUSIONS: Studying cytogenetic changes of MSCs in a variety of leukemias will help researchers understand the nature of these tumors and ensure the safety of human stem cells in clinical applications.

Keywords bone marrow mesenchymal stromal cells leukemia cytogenetic niche

Corresponding Author(s): Najmaldin Saki

Just Accepted Date: 21 June 2016 Online First Date: 18 July 2016 Issue Date: 30 August 2016

Cite this article:

Shirin Ferdowsi,Shirin Azizidoost,Nasim Ghafari, et al. Cytogenetic changes of mesenchymal stem cells in the neoplastic bone marrow niche in leukemia[J]. Front. Biol., 2016, 11(4): 305-310.

URL:

https://academic.hep.com.cn/fib/EN/10.1007/s11515-016-1408-0
https://academic.hep.com.cn/fib/EN/Y2016/V11/I4/305

Tab.1 Cytogenetic aberrations in BM-MSCs from leukemia patients.

1	Achille V, Mantelli M, Arrigo G, Novara F, Avanzini M A, Bernardo M E, Zuffardi O, Barosi G, Zecca M, Maccario R (2011). Cell-cycle phases and genetic profile of bone marrow-derived mesenchymal stromal cells expanded in vitro from healthy donors. J Cell Biochem, 112(7): 1817–1821 https://doi.org/10.1002/jcb.23100 pmid: 21400572
2	Arnulf B, Lecourt S, Soulier J, Ternaux B, Lacassagne M N, Crinquette A, Dessoly J, Sciaini A K, Benbunan M, Chomienne C, Fermand J P, Marolleau J P, Larghero J (2007). Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma. Leukemia, 21(1): 158–163 https://doi.org/10.1038/sj.leu.2404466 pmid: 17096013
3	Avanzini M A, Bernardo M E, Novara F, Mantelli M, Poletto V, Villani L, Lenta E, Ingo D M, Achille V, Bonetti E, Massa M, Campanelli R, Fois G, Catarsi P, Gale R P, Moretta A, Aronica A, Maccario R, Acquafredda G, Lisini D, Zecca M, Zuffardi O, Locatelli F, Barosi G, Rosti V, the AGIMM Investigators (2014). Functional and genetic aberrations of in vitro-cultured marrow-derived mesenchymal stromal cells of patients with classical Philadelphia-negative myeloproliferative neoplasms. Leukemia, 28(8): 1742–1745 https://doi.org/10.1038/leu.2014.97 pmid: 24618733
4	Azizidoost S, Babashah S, Rahim F, Shahjahani M, Saki N (2014). Bone marrow neoplastic niche in leukemia. Hematology, 19(4): 232–238 https://doi.org/10.1179/1607845413Y.0000000111 pmid: 23905984
5	Bacher U, Asenova S, Badbaran A, Zander A R, Alchalby H, Fehse B, Kröger N, Lange C, Ayuk F (2010). Bone marrow mesenchymal stromal cells remain of recipient origin after allogeneic SCT and do not harbor the JAK2V617F mutation in patients with myelofibrosis. Clin Exp Med, 10(3): 205–208 https://doi.org/10.1007/s10238-009-0058-9 pmid: 19629639
6	Balakrishnan K, Burger J A, Quiroga M P, Henneberg M, Ayres M L, Wierda W G, Gandhi V (2010). Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells. Blood, 116(7): 1083–1091 https://doi.org/10.1182/blood-2009-10-246199 pmid: 20442367
7	Bernasconi P (2008). Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions-a review. Br J Haematol, 142(5): 695–708 https://doi.org/10.1111/j.1365-2141.2008.07245.x pmid: 18540941
8	Bhatia R, McGlave P B, Dewald G W, Blazar B R, Verfaillie C M (1995). Abnormal function of the bone marrow microenvironment in chronic myelogenous leukemia: role of malignant stromal macrophages. Blood, 85(12): 3636–3645 pmid: 7780147
9	Blau O, Baldus C D, Hofmann W K, Thiel G, Nolte F, Burmeister T, Türkmen S, Benlasfer O, Schümann E, Sindram A, Molkentin M, Mundlos S, Keilholz U, Thiel E, Blau I W (2011). Mesenchymal stromal cells of myelodysplastic syndrome and acute myeloid leukemia patients have distinct genetic abnormalities compared with leukemic blasts. Blood, 118(20): 5583–5592 https://doi.org/10.1182/blood-2011-03-343467 pmid: 21948175
10	Blau O, Hofmann W K, Baldus C D, Thiel G, Serbent V, Schümann E, Thiel E, Blau I W (2007). Chromosomal aberrations in bone marrow mesenchymal stroma cells from patients with myelodysplastic syndrome and acute myeloblastic leukemia. Exp Hematol, 35(2): 221–229 https://doi.org/10.1016/j.exphem.2006.10.012 pmid: 17258071
11	Borovski T, De Sousa E Melo F, Vermeulen L, Medema J P (2011). Cancer stem cell niche: the place to be. Cancer Res, 71(3): 634–639 https://doi.org/10.1158/0008-5472.CAN-10-3220 pmid: 21266356
12	Campioni D, Bardi M A, Cavazzini F, Tammiso E, Pezzolo E, Pregnolato E, Volta E, Cuneo A, Lanza F (2012). Cytogenetic and molecular cytogenetic profile of bone marrow-derived mesenchymal stromal cells in chronic and acute lymphoproliferative disorders. Ann Hematol, 91(10): 1563–1577 https://doi.org/10.1007/s00277-012-1500-8 pmid: 22696050
13	Carrara R C, Orellana M D, Fontes A M, Palma P V, Kashima S, Mendes M R, Coutinho M A, Voltarelli J C, Covas D T (2007). Mesenchymal stem cells from patients with chronic myeloid leukemia do not express BCR-ABL and have absence of chimerism after allogeneic bone marrow transplant. Braz J Med Biol Res, 40(1): 57–67 https://doi.org/10.1590/S0100-879X2007000100008 pmid: 17224997
14	Choumerianou D M, Dimitriou H, Perdikogianni C, Martimianaki G, Riminucci M, Kalmanti M (2008). Study of oncogenic transformation in ex vivo expanded mesenchymal cells, from paediatric bone marrow. Cell Prolif, 41(6): 909–922 https://doi.org/10.1111/j.1365-2184.2008.00559.x pmid: 19040569
15	Corre J, Mahtouk K, Attal M, Gadelorge M, Huynh A, Fleury-Cappellesso S, Danho C, Laharrague P, Klein B, Rème T, Bourin P (2007). Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia, 21(5): 1079–1088 pmid: 17344918
16	Dimitriou H, Linardakis E, Martimianaki G, Stiakaki E, Perdikogianni C H, Charbord P, Kalmanti M (2008). Properties and potential of bone marrow mesenchymal stromal cells from children with hematologic diseases. Cytotherapy, 10(2): 125–133 https://doi.org/10.1080/14653240701851332 pmid: 18368591
17	Ferretti E, Bertolotto M, Deaglio S, Tripodo C, Ribatti D, Audrito V, Blengio F, Matis S, Zupo S, Rossi D, Ottonello L, Gaidano G, Malavasi F, Pistoia V, Corcione A (2011). A novel role of the CX3CR1/CX3CL1 system in the cross-talk between chronic lymphocytic leukemia cells and tumor microenvironment. Leukemia, 25(8): 1268–1277 https://doi.org/10.1038/leu.2011.88 pmid: 21546901
18	Flores-Figueroa E, Arana-Trejo R M, Gutiérrez-Espíndola G, Pérez-Cabrera A, Mayani H (2005). Mesenchymal stem cells in myelodysplastic syndromes: phenotypic and cytogenetic characterization. Leuk Res, 29(2): 215–224 https://doi.org/10.1016/j.leukres.2004.06.011 pmid: 15607371
19	Garayoa M, Garcia J L, Santamaría C, Garcia-Gomez A, Blanco J F, Pandiella A, Hernández J M, Sanchez-Guijo F M, del Cañizo M C, Gutiérrez N C, San Miguel J F (2009). Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors. Leukemia, 23(8): 1515–1527 https://doi.org/10.1038/leu.2009.65 pmid: 19357701
20	Garderet L, Mazurier C, Chapel A, Ernou I, Boutin L, Holy X, Gorin N C, Lopez M, Doucet C, Lataillade J J (2007). Mesenchymal stem cell abnormalities in patients with multiple myeloma. Leuk Lymphoma, 48(10): 2032–2041 https://doi.org/10.1080/10428190701593644 pmid: 17917971
21	Haniffa M A, Wang X N, Holtick U, Rae M, Isaacs J D, Dickinson A M, Hilkens C M, Collin M P (2007). Adult human fibroblasts are potent immunoregulatory cells and functionally equivalent to mesenchymal stem cells. J Immunol, 179(3): 1595–1604 https://doi.org/10.4049/jimmunol.179.3.1595 pmid: 17641026
22	Huang J C, Basu S K, Zhao X, Chien S, Fang M, Oehler V G, Appelbaum F R, Becker P S (2015). Mesenchymal stromal cells derived from acute myeloid leukemia bone marrow exhibit aberrant cytogenetics and cytokine elaboration. Blood Cancer J, 5(4): e302 https://doi.org/10.1038/bcj.2015.17 pmid: 25860293
23	James C (2008). The JAK2V617F mutation in polycythemia vera and other myeloproliferative disorders: one mutation for three diseases? ASH Education Program Book, 2008(1): 69–75
24	Jootar S, Pornprasertsud N, Petvises S, Rerkamnuaychoke B, Disthabanchong S, Pakakasama S, Ungkanont A, Hongeng S (2006). Bone marrow derived mesenchymal stem cells from chronic myeloid leukemia t(9;22) patients are devoid of Philadelphia chromosome and support cord blood stem cell expansion. Leuk Res, 30(12): 1493–1498 https://doi.org/10.1016/j.leukres.2006.04.013 pmid: 16839603
25	Kastrinaki M C, Pontikoglou C, Klaus M, Stavroulaki E, Pavlaki K, Papadaki H A (2011). Biologic characteristics of bone marrow mesenchymal stem cells in myelodysplastic syndromes. Curr Stem Cell Res Ther, 6(2): 122–130 https://doi.org/10.2174/157488811795495422 pmid: 20528751
26	Keating A (2006). Mesenchymal stromal cells. Curr Opin Hematol, 13(6): 419–425 https://doi.org/10.1097/01.moh.0000245697.54887.6f pmid: 17053453
27	Kemp K, Morse R, Sanders K, Hows J, Donaldson C (2011). Alkylating chemotherapeutic agents cyclophosphamide and melphalan cause functional injury to human bone marrow-derived mesenchymal stem cells. Ann Hematol, 90(7): 777–789 https://doi.org/10.1007/s00277-010-1141-8 pmid: 21234567
28	Klaus M, Stavroulaki E, Kastrinaki M C, Fragioudaki P, Giannikou K, Psyllaki M, Pontikoglou C, Tsoukatou D, Mamalaki C, Papadaki H A (2010). Reserves, functional, immunoregulatory, and cytogenetic properties of bone marrow mesenchymal stem cells in patients with myelodysplastic syndromes. Stem Cells Dev, 19(7): 1043–1054 https://doi.org/10.1089/scd.2009.0286 pmid: 19788374
29	Lopez-Villar O, Garcia J L, Sanchez-Guijo F M, Robledo C, Villarón E M, Hernández-Campo P, Lopez-Holgado N, Diez-Campelo M, Barbado M V, Perez-Simon J A, Hernández-Rivas J M, San-Miguel J F, del Cañizo M C (2009). Both expanded and uncultured mesenchymal stem cells from MDS patients are genomically abnormal, showing a specific genetic profile for the 5q- syndrome. Leukemia, 23(4): 664–672 https://doi.org/10.1038/leu.2008.361 pmid: 19151777
30	Mahtouk K, Hose D, Rème T, De Vos J, Jourdan M, Moreaux J, Fiol G, Raab M, Jourdan E, Grau V, Moos M, Goldschmidt H, Baudard M, Rossi J F, Cremer F W, Klein B (2005). Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells. Oncogene, 24(21): 3512–3524 https://doi.org/10.1038/sj.onc.1208536 pmid: 15735670
31	Menendez P, Catalina P, Rodríguez R, Melen G J, Bueno C, Arriero M, García-Sánchez F, Lassaletta A, García-Sanz R, García-Castro J (2009). Bone marrow mesenchymal stem cells from infants with MLL-AF4+ acute leukemia harbor and express the MLL-AF4 fusion gene. J Exp Med, 206(13): 3131–3141 https://doi.org/10.1084/jem.20091050 pmid: 19995953
32	Mercier F, Monczak Y, François M, Prchal J, Galipeau J (2009). Bone marrow mesenchymal stromal cells of patients with myeloproliferative disorders do not carry the JAK2-V617F mutation. Exp Hematol, 37(3): 416–420 https://doi.org/10.1016/j.exphem.2008.11.008 pmid: 19135773
33	Mitsiades C S, McMillin D W, Klippel S, Hideshima T, Chauhan D, Richardson P G, Munshi N C, Anderson K C (2007). The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies. Hematol Oncol Clin North Am, 21(6): 1007–1034, vii–viii https://doi.org/10.1016/j.hoc.2007.08.007 pmid: 17996586
34	Nussenzveig R H, Swierczek S I, Jelinek J, Gaikwad A, Liu E, Verstovsek S, Prchal J T (2007). Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol, 35(1): 32. e31–32,e39
35	Oliveira F M, Lucena-Araujo A R, Favarin M C, Palma P V, Rego E M, Falcão R P, Covas D T, Fontes A M (2013). Differential expression of AURKA and AURKB genes in bone marrow stromal mesenchymal cells of myelodysplastic syndrome: correlation with G-banding analysis and FISH. Exp Hematol, 41(2): 198–208 https://doi.org/10.1016/j.exphem.2012.10.009 pmid: 23092930
36	Oshima T, Abe M, Asano J, Hara T, Kitazoe K, Sekimoto E, Tanaka Y, Shibata H, Hashimoto T, Ozaki S, Kido S, Inoue D, Matsumoto T (2005). Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood, 106(9): 3160–3165 https://doi.org/10.1182/blood-2004-12-4940 pmid: 16030194
37	Pieri L, Guglielmelli P, Bogani C, Bosi A, Vannucchi A M, Consortium M D R, and the Myeloproliferative Disorders Research Consortium (MPD-RC) (2008). Mesenchymal stem cells from JAK2(V617F) mutant patients with primary myelofibrosis do not harbor JAK2 mutant allele. Leuk Res, 32(3): 516–517 https://doi.org/10.1016/j.leukres.2007.07.001 pmid: 17706283
38	Pimenova M A, Parovichnikova E N, Kokhno A V, Domracheva E V, Manakova T E, Mal’tseva IuS, Konnova M L, Shishigina L A, Savchenko V G (2013). Cytogenetic characteristics of hematopoietic and stromal progenitor cells in myelodysplastic syndrome. Ter Arkh, 85(7): 34–42 pmid: 24137945
39	Podar K, Richardson P G, Hideshima T, Chauhan D, Anderson K C (2007). The malignant clone and the bone-marrow environment. Best Pract Res Clin Haematol, 20(4): 597–612 https://doi.org/10.1016/j.beha.2007.08.002 pmid: 18070708
40	Ramasamy R, Lam E W, Soeiro I, Tisato V, Bonnet D, Dazzi F (2007). Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: impact on in vivo tumor growth. Leukemia, 21(2): 304–310 https://doi.org/10.1038/sj.leu.2404489 pmid: 17170725
41	Saki N, Abroun S, Farshdousti Hagh M, Asgharei F (2011). Neoplastic bone marrow niche: hematopoietic and mesenchymal stem cells. Cell J, 13(3): 131–136 pmid: 23508881
42	Shahrabi S, Azizidoost S, Shahjahani M, Rahim F, Ahmadzadeh A, Saki N (2014). New insights in cellular and molecular aspects of BM niche in chronic myelogenous leukemia. Tumour Biol, 35(11): 10627–10633 https://doi.org/10.1007/s13277-014-2610-9 pmid: 25234716
43	Soenen-Cornu V, Tourino C, Bonnet M L, Guillier M, Flamant S, Kotb R, Bernheim A, Bourhis J H, Preudhomme C, Fenaux P, Turhan A G (2005). Mesenchymal cells generated from patients with myelodysplastic syndromes are devoid of chromosomal clonal markers and support short- and long-term hematopoiesis in vitro. Oncogene, 24(15): 2441–2448 https://doi.org/10.1038/sj.onc.1208405 pmid: 15735749
44	Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, Shaughnessy J D Jr (2003). The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med, 349(26): 2483–2494 https://doi.org/10.1056/NEJMoa030847 pmid: 14695408
45	Wallace S R, Oken M M, Lunetta K L, Panoskaltsis-Mortari A, Masellis A M (2001). Abnormalities of bone marrow mesenchymal cells in multiple myeloma patients. Cancer, 91(7): 1219–1230 https://doi.org/10.1002/1097-0142(20010401)91:7<1219::AID-CNCR1122>3.0.CO;2-1 pmid: 11283920
46	Wöhrer S, Rabitsch W, Shehata M, Kondo R, Esterbauer H, Streubel B, Sillaber C, Raderer M, Jaeger U, Zielinski C, Valent P (2007). Mesenchymal stem cells in patients with chronic myelogenous leukaemia or bi-phenotypic Ph+ acute leukaemia are not related to the leukaemic clone. Anticancer Res, 27(6B): 3837–3841 pmid: 18225540
47	Yeh S P, Lo W J, Lin C L, Liao Y M, Lin C Y, Bai L Y, Liang J A, Chiu C F (2012). Anti-leukemic therapies induce cytogenetic changes of human bone marrow-derived mesenchymal stem cells. Ann Hematol, 91(2): 163–172 https://doi.org/10.1007/s00277-011-1254-8 pmid: 21573981
48	Zdzisińska B, Bojarska-Junak A, Dmoszyńska A, Kandefer-Szerszeń M (2008). Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells. Arch Immunol Ther Exp (Warsz), 56(3): 207–221 https://doi.org/10.1007/s00005-008-0022-5 pmid: 18512025
49	Zhan F, Huang Y, Colla S, Stewart J P, Hanamura I, Gupta S, Epstein J, Yaccoby S, Sawyer J, Burington B, Anaissie E, Hollmig K, Pineda-Roman M, Tricot G, van Rhee F, Walker R, Zangari M, Crowley J, Barlogie B, Shaughnessy J D Jr (2006). The molecular classification of multiple myeloma. Blood, 108(6): 2020–2028 https://doi.org/10.1182/blood-2005-11-013458 pmid: 16728703

[1]	Anatoliy I. Bozhkov, Eugeniy G. Ivanov, Yuliya A. Kuznetsova, Svetlana L. Ohiienko, Anastasiya Yu. Bondar’. Copper-induced liver fibrosis affects the behavior of bone marrow cells in primary culture[J]. Front. Biol., 2017, 12(4): 271-279.
[2]	Ali Amin Asnafi,Elahe Khodadi,Neda Golchin,Arash Alghasi,Yousef Tavakolifar,Najmaldin Saki. Association between microRNA-21, microRNA-150, and microRNA-451 expression and clinical outcome of patients with acute lymphoblastic leukemia[J]. Front. Biol., 2017, 12(1): 63-70.
[3]	Jian Li,Chun Guo,Nickolas Steinauer,Jinsong Zhang. New insights into transcriptional and leukemogenic mechanisms of AML1-ETO and E2A fusion proteins[J]. Front. Biol., 2016, 11(4): 285-304.
[4]	Farzaneh Tavakoli,Kaveh Jaseb,Mohammad Ali Jalali Far,Masoud Soleimani,Elahe Khodadi,Najmaldin Saki. Evaluation of microRNA-146a expression in acute lymphoblastic leukemia[J]. Front. Biol., 2016, 11(1): 53-58.
[5]	Vipul SHUKLA,Runqing LU. IRF4 and IRF8: governing the virtues of B lymphocytes[J]. Front. Biol., 2014, 9(4): 269-282.
[6]	Yinghui HUANG, Xiaoxue QIU, Ji-Long CHEN. Identification of cancer stem cells: from leukemia to solid cancers[J]. Front Biol, 2010, 5(5): 407-416.
[7]	TAO Yongsheng, ZHANG Zuxin, CHEN Yonglin, LI Lijia, ZHENG Yonglian. Technological exploration of BAC-FISH on mitotic chromosomes of maize[J]. Front. Biol., 2008, 3(4): 414-418.
[8]	ZHOU Shurong, ZHANG Dayong. Neutral theory in community ecology[J]. Front. Biol., 2008, 3(1): 1-8.
[9]	FU Heping, WU Xiaodong, YANG Zelong. Niche characteristics of rodents by diverse disturbance in Alashan desert, Inner Mongolia, China[J]. Front. Biol., 2007, 2(4): 456-462.

Viewed

Full text

Abstract

Cited

Shared

Discussed